Arqule

Merck wraps up $2.7bn acquisition of biopharmaceutical firm ArQule
Merck wraps up $2.7bn acquisition of biopharmaceutical firm ArQule
Pharmaceutical Business Review
Merck
Arqule
M&A
Flag link:
Why Biotech Stock ArQule Soared 108% in December
Why Biotech Stock ArQule Soared 108% in December
Motley Fool
Merck
Arqule
M&A
Flag link:
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
Marketwatch
Merck
M&A
Arqule
oncology
Flag link:
3 Soaring Biotech Stocks to Watch in December
3 Soaring Biotech Stocks to Watch in December
Motley Fool
Arrowhead Pharmaceuticals
RNAi
Adverum Biotechnologies
gene therapy
ADVM-022
Arqule
ARQ-531
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
EHA 2019 – turnaround puts Arqule in the takeover frame
EHA 2019 – turnaround puts Arqule in the takeover frame
EP Vantage
Arqule
ARQ 531
EHA
Btk inhibitors
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
Imbruvica resistance provides early but fertile development ground
Imbruvica resistance provides early but fertile development ground
EP Vantage
Arqule
Imbruvica
drug development
Btk inhibitors
Flag link:
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
CP WIre
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Flag link:
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
Arqule
Basilea
Roche
BAL087
urothelial cancer
Tecentriq
Flag link:
The 4 Best Biotech Stocks of 2018 (So Far)
The 4 Best Biotech Stocks of 2018 (So Far)
Motley Fool
biotech
Arrowhead Research
Endocyte
Arqule
Madrigal Pharmaceuticals
Flag link:
4 Biotech Stocks That Tripled in the First Half of 2018
4 Biotech Stocks That Tripled in the First Half of 2018
Motley Fool
biotech
biotech stocks
Arrowhead Pharmaceuticals
Arqule
Endocyte
Madrigal Pharmaceuticals
Flag link:
Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Endpoints
Daiichi Sankyo
Pieris
DS-9001
tivantinib
Arqule
Flag link:
Daiichi, ArQule cancer drug fails in late-stage study
Daiichi, ArQule cancer drug fails in late-stage study
BioPharma Dive
Daiichi Sankyo
Arqule
clinical trials
tivantinib
liver cancer
Flag link:
Battered ArQule shares bump up on badly needed positive data for tivantinib
Battered ArQule shares bump up on badly needed positive data for tivantinib
Fierce Biotech
Arqule
tivantinib
metastatic prostate cancer
Flag link:
ArQule shares rise after committee say liver cancer study can continue with lower drug dose
ArQule shares rise after committee say liver cancer study can continue with lower drug dose
Yahoo/AP
Arqule
liver cancer
FDA
tivantinib
Flag link:
Data on ArQule's Tivantinib
Data on ArQule's Tivantinib
Yahoo/Zacks
Arqule
tivantinib
Daiichi Sankyo
lung cancer
non-small cell lung cancer
Flag link:
ArQule up on hope for lung cancer drug revival
ArQule up on hope for lung cancer drug revival
Reuters
Arqule
tivantinib
Daiichi Sankyo
lung cancer
Flag link:
ArQule to cut liver cancer drug dose on safety concerns
ArQule to cut liver cancer drug dose on safety concerns
Reuters
Arqule
liver cancer
tivantinib
Flag link:

Pages